

Bassett Cancer Institute  
**Cancer Treatment  
with Pluvicto**

**The Bassett Cancer Institute team will collaborate with your primary oncologist to develop an overall care plan that will work best for you.**

For more information about Pluvicto therapy, or for any questions about cancer symptoms or treatment, please call the Bassett Cancer Institute at 607-547-3336.

**Visit [Bassett.org/Pluvicto](https://www.bassett.org/Pluvicto)**

**IMPORTANT SAFETY INFORMATION <sup>1</sup>**

**APPROVED USE:**

PLUVICTO™ is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer that has spread to other parts of the body (metastatic), and has already been treated with other anticancer treatments.

<sup>1</sup> [www.us.pluvicto.com](https://www.us.pluvicto.com)



**Bassett Healthcare Network**

One Atwell Road  
Cooperstown, NY 13326  
(607) 547-3456 • 1-800-BASSETT  
[www.bassett.org](https://www.bassett.org)

4/23 Form #10442



**Bassett Healthcare Network**

# Bassett Cancer Institute

Every member of our team works together to offer every patient a comprehensive, personalized treatment plan that combines cutting-edge technologies with the expertise of specialists from many fields.

The nationally accredited medical, radiation, and surgical oncologists, as well as oncology certified registered nurses at the Bassett Cancer Institute work alongside laboratory personnel, nutritional counselors, social workers, financial counselors, and nurse navigators to ensure patients are receiving the highest level of cancer care.

**The Bassett Cancer Institute is the first to offer Pluvicto treatments in our region of Central New York State and we're proud to provide this therapy to our patients.**

## What is Pluvicto?

This innovative treatment is a cancer therapy for adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA+ mCRPC). Pluvicto:

- Delivers radiation directly to the cancer cells which slows or even stops tumor growth altogether.
- May also help to manage symptoms caused by the tumors.
- Can drastically improve outcomes for PSMA+ mCRPC.

*This brochure may help answer some of the questions you may have about PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan). This brochure is not intended to replace advice given to you by your health care practitioner (HCP). You should always speak with your HCP about any questions you may have.*

## How Is It Different?

Pluvicto's ability to target specific cells with radiation sets this treatment apart from other therapies used to treat PSMA+ mCRPC.

Most radiation treatments are external, aiming multiple beams of radiation at a tumor from many angles outside the body at the same time. With PSMA+ mCRPC tumors, this method cannot safely treat all of the disease.

Pluvicto is more efficient and effective than external therapies because it:

- Works inside the body to enter the cancerous cells.
- Directly releases radiation that damages and kills the tumor cells from the inside.

## What to Expect During Treatment

Patients receiving Pluvicto therapy at Bassett Cancer Institute will:

- Spend a few hours at Bassett's Cancer Treatment Center.
- Be given medications to prevent nausea at the discretion of the practitioner.
- Have the Pluvicto delivered as a simple intravenous (IV) infusion over the course of a half hour, with close physician and nurse supervision.
- Repeat this treatment every 6-weeks, for a total of six treatments.

## What to Expect After Treatment

After each Pluvicto treatment patients:

- Will receive special radiation safety instructions for use at home.
- Will receive frequent lab testing to make sure that the different types of cells in their blood stay at normal levels during treatment. These blood tests can be done conveniently at a lab or clinic near your home.
- Follow-up visits between treatments can be done either in-person or by phone or video through telemedicine without the need to travel.